The Business Journals14d
Johnston County braces for more growth with $4 billion expansion ahead
Pharmaceutical giant Novo Nordisk (NYSE: NVO) in 2024 launched a $4 billion expansion in Clayton that the Danish company says will create 1,000 new jobs ... Large NC shopping center sells for ...
Bloomberg L.P.14d
Novo Nordisk Shares Have a Long Road Back from 40% Slump
Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of the past ...
Kaleido Scope14d
Live HealthSmart Alabama expands to central Alabama thanks to gift from Novo Nordisk, Inc.
Live HealthSmart Alabama With a $2.47 million gift from Novo Nordisk Inc., Live HealthSmart Alabama is applying ... working with local leaders to address pressing needs like new, wind-resistant roofs ...
Insider Monkey15d
Jim Cramer on Novo Nordisk A/S (NVO): ‘They Don’t Have The Production Capability’
In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... Wegovy semaglutide drug was first to market among the new generation of obesity drugs; however, the company has ...
India TV15d
US FDA approves Novo Nordisk's Ozempic to reduce risk of kidney diseases in diabetic patients
The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the risk of kidney failure and disease progression. According to a statement made by the Danish ...
Business Insider17d
Shareholders that lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO
NEW YORK, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities ...
NBC Washington17d
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...
Euronews18d
Novo Nordisk shares surge on results of new obesity drug trial
the Danish pharmaceutical company experienced a 21% plunge in its share price following disappointing trial results for its new obesity drug, CagriSema. Amycretin is considered as Novo Nordisk’s ...
Yahoo Finance20d
Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin
Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the company's ...
Fortune21d
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise
Novo Nordisk hopes the new treatment can build on the success of its flagship obesity drug, Wegovy. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this ...
MarketWatch21d
Ozempic maker’s stock surges. A trial of a new Novo Nordisk drug shows promise.
Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%. Novo Nordisk said a Phase 1b/2a clinical trial of amycretin ...